Comparative study of misoprostol and nifedipine for the treatment of Raynaud phenomenon secondary to systemic diseases. Doppler-duplex hemodynamic evaluation;Estudio comparativo de misoprostol y nifedipino en el tratamiento del fenomeno de Raynaud secundario a enfermedades sistemicas. Valoracion hemodinamica mediante Doppler-duplex

Revista Clinica Espanola

Volumn 197, Issue 2, 1997, Pages 77-83

  Varela Aguilar, J M ^a,b   Sanchez Roman J ^a   Talegon Melendez A ^a   Castillo Palma, Ma J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b NONE   (Spain)

Author keywords

Doppler duplex; misoprostol; nifedipine; prostaglandin; Raynaud phenomenon

Indexed keywords

MISOPROSTOL; NIFEDIPINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODYNAMICS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON;

EID: 0030961473     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Raynaud M On local asphyxia and symmetrical gangrene of the extremities and new researches on the nature and treatment of local asphyxia of the extremities. En: Barlow T, ed. Selected Monographs. London- New Sydenham Soc Publ 1888, 1-199
2. Hutchinson J. Raynaud's phenomenona. Med Press Circ 1901: 123: 403-405
3. Rodnan GP, Myerowitz RL, O'Justh G. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon Medicine 1980; 595:393-408.
4. Furchgott RF, Zawadzki JV The obligatory role of endotelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
5. Cleophas TJM, Niemeyer MG Raynaud's syndrome, an enigma after 130 years. Angiology 1993; 44 196-209.
6. Carlson LA, Olsson AG. Intravenous prostaglandine E1 in severe peripheral vascular disease. Lancet 1976; ii:810.
7. Fiessinger JN, Schäfer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet 1990; 335: 555-557.
8. Bedani PL, Perini L, Farinelli R, et al. Favorable clinical effects of iloprost infusion in 4 uremic patients with critical limb ischemia. Angiology 1992; 43:408-411.
9. Belch JJ, Newman P, Drury JK, et al. Succesful treatment of Raynaud's syndrome with prostacyclin. Thrombos Haemostas 1981; 45:255-256
10. Martin MF, Dowd PM, Ring EF, Cooke ED, Dieppe PA, Kirby JD. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 1981; 40:350-354.
11. Kyle V, Parr G, Salisbury R, Thomas PP, Hazleman B Prostaglandin E1, vasospastic disease and thermography. Ann Rheum Dis 1985; 44:73-78.
12. 1 infusions. J Rheumatol 1989; 16:1.433-1.435.
13. Shono T, Ikeda K Rapid effect of oral limaprost in Raynaud's disease in childhood. Lancet 1989; i:908.
14. Murai C, Sasaki T, Osaka H, Hatakeyama A, Shibata S, Yoshinaga K Oral limaprost for Raynaud s disease. Lancet 1989; ii:1.218.
15. Tsukamoto H, Nagasawa K. Succesful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E1 analogue Br J Rheumatol 1991; 30:317.
16. Lau CS, McLaren M, Saniabadi A, Scott N, Belch JJF. The pharmacological effects of cicaprost. an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis - a preliminary study. Clin Exp Rheumatol 1991; 9:271-272.
17. Belch JJF, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynayd's syndrome: a double blind multicentre controlled study. Ann Rheum Dis 1995; 54:197-200
18. 2 analogue, in treatment of Raynaud's phenomenon Lancet 1985; i:1 180-1.183.
19. 2 analogue Lancet 1985; ii:50.
20. Tan E, Cohen A, Fries JF, et al The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1 271-1.277
21. Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis Rheum 1980; 23: 581-590
22. Bohan A, Peter JB Polymiositis and dermatomyositis N Engl J Med 1975; 292 344-347.
23. Bohan A, Peter JB Polymiositis and dermatomyositis N Engl J Med 1975; 292:403-407
24. Gosling RG, Dunbar G, King DH, et al. The quantitative analysis of occlusive peripheral arterial disease by a non-invasive ultrasonic technique. Angiology 1971; 22:52-55
25. Lewis P, Psaila JV, Davies WT, McCarthy K, Woodcock JP. Measurement of volume flow in the human common femoral artery using a duplex ultrasound system. Ultrasound Med Biol 1986; 12:777-784.
26. Campbell PM, LeRoy EC. Raynaud phenomen Semin Arthritis Rheum 1986; 16:92-103.
27. Spencer-Greemn G Raynaud phenomenon Bull Rheum Dis 1983; 33 1-8
28. Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of rafedipine in the treatment of Raynaud s phenomenon N Engl J Med 1983; 303 880-883
29. Morgan RH, Psaila JV, Davies WT, Carolan G, Woodcock JP Digital and radial artery blood flow in patients with Raynaud's phenomenon in response to nifedipine. Eur J Vasc Surg 1987; 6:1 403-1.408
30. Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M Etude controlee de la nifédipine dans le traitement du phénomene de Raynaud Rev Rhum Mal Osteoartic 1982; 49:337-343
31. Smith CD, McKendry RJ. Controlled trial of nifedipine in the treatment of Raynaud s phenomenon Lancet 1982; ii:1 299-1.301
32. Nilsson H, Jonason T, Leppert J, Ringovist I The effect of the calcium-entry blocker nifedipine on cold-induced digital vasospasm. Acta Med Scand 1987; 221:53-60
33. Lewis P, Psaila JV, Morgan RH, Davies WT, Woodcock JP Nifedipine in patients with Raynaud's syndrome - effects on radial artery blood flow Eur Heart J 1987; 8K 83-86
34. Wise RA, Wigley F Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon J Rheumatol 1994; 21;80-83.
35. Torley HI, Madhok R, Capell HA, et al. A double blind, randomized, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud s phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991; 50:800-804.
36. 1. Br Med J 1980; 281:1.031-1.034
37. Yardumian DA, Isenberg DA, Rustin M, et al. Succesful treatment of Raynaud's syndrome with iloprost. a chemically stable prostacyclin analogue Br J Rheumatol 1988; 27:220-226.
38. Watson HR, Belcher G Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon. Ann Rheum Dis 1991; 50:359-361.
39. Belluci S, Kedra AW, Courmelle JM, et al Prolonged remission in Raynaud's phenomenon after prostacyclin infusion. Scand J Rheumatol 1986; 15:392-398
40. Rademaker M, Thomas RHM, Provost G, Beacham JA, Cooke ED, Kirby JD Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J 1987; 63:617-620
41. Kahan A, Weber S, Amor B, et al Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon). Eur Heart J 1983; 4 (suppl C): 123-129
42. Winston EL, Panser KM, Miller KB, Salem DN, Creager MA. Nifedipine as a therapeutic modality for Raynaud's phenomenon. Arthritis Rheum 1983; 26:1 117-1.180.
43. Sauza J, Kraus A, González-Amaro R, Alarcón Segovia D. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial. J Rheumatol 1984; 11:362-364
44. Schmidt JF, Valentín N, Levin S. The clinical effect of felodipine and nifedipine in Raynaud s phenomenon. Eur J Clin Pharmacol 1989; 37: 191-192
45. Cleophas TJM Understimation of treatment effect in crossover trials. Angiology 1990; 41: 673-680.
46. Corbin DO, Wood DA, Macintyre CC, Housley E. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Eur Heart J 1986; 7:165-170.
47. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis, a double-blind randomized study Br Med J 1989; 298:561-564.
48. Ettinger WH, Wise RA, Schaffhauser D, Wigley FM Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1984; 77:451-456.
49. McHugh NJ, Csuka M, Watson H, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon. Ann Rheum Dis 1988; 47:43-47.
50. Meyrick RH, Rademaker M, Grimes SM, et al Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis Br J Dermatol 1987; 117:237-241.
51. Codella O, Cramaschi P, Olivieri O, et al. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon. Angiology 1989; 40:114-121
52. Wise RA, Malamet R, Wigley FM Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial. J Rheumatol 1987; 14:278-283.
53. Smith CR, Rodeheffer RH Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers. Am J Cardiol 1985; 55:154B-157B
54. Cardelli MB, Kleinsmith DM. Raynaud's phenomenon and disease. Med Clin N Am 1989; 73.1 127-1 141
55. Gjorup T, Kelbaek H, Hatling OJ, Nielsen SL Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon Am Heart J 1986; 111:742-745.
56. 2). Br J Dermatol 1982; 106:81-89
57. Waller DG, Challenor VF, Francis DA, Roath OS Clinical and rheological effects of nifedipine in Raynaud s phenomenon. Br J Clin Pharmac 1986; 22:449-454